Resverlogix Corp. (TSX: RVX) is developing apabetalone (RVX-208), a first-in-class, small molecule selective BET bromodomain inhibitor. Apabetalone is the only selective BET bromodomain inhibitor in clinical trials. BET bromodomain inhibition is an epigenetic mechanism that can turn disease-causing genes off, returning them to a healthier state. Apabetalone is the first and only BET inhibitor selective for BRD4-BD2, producing a nexus of biological effects with potentially important benefits for patients with diseases such as cardiovascular disease, diabetes mellitus, chronic kidney disease, peripheral artery disease, Orphan diseases (PNH), and Alzheimer's disease, while maintaining a well described safety profile. Resverlogix has commenced a Phase 3 clinical trial in CVD patients with type 2 DM and low HDL, with a primary endpoint of time to first occurrence of Major Adverse Cardiac Events (MACE).
Our Business Model is to seek strategic opportunities through early alliance partnerships that are best suited to bring our technology platforms to successful commercialization. We are committed to good corporate governance and protection of shareholder value.
Last changed at 31-Jan-2019 06:13PM by BearDownAZ